Department of Critical Care, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom.
Faculty of Life Sciences & Medicine, King's College London, London, United Kingdom.
Crit Care Med. 2019 Feb;47(2):e81-e88. doi: 10.1097/CCM.0000000000003515.
To investigate the safety of percutaneous dilatational tracheostomy in severe respiratory failure patients during veno-venous extracorporeal membrane oxygenation support.
A single-center, retrospective, observational cohort study.
Tertiary referral severe respiratory failure center, university teaching hospital.
Severe respiratory failure patients consecutively admitted and supported with veno-venous extracorporeal membrane oxygenation between January 2010 and December 2015.
A bronchoscopy-guided percutaneous dilatational tracheostomy was performed in all cases.
Sixty-five veno-venous extracorporeal membrane oxygenation patients (median [interquartile range] age, 47 yr [interquartile range, 35-59 yr]; 39 males; Acute Physiology and Chronic Health Evaluation-II score, 18 [interquartile range, 17-22] Sequential Organ Failure Assessment score, 10 [interquartile range, 7-16]) underwent percutaneous dilatational tracheostomy. Ten patients (15%) developed one or more major complications. Of these, seven (11%) had major bleeding, and three of these also required circuit change due to extracorporeal membrane oxygenation circuit dysfunction. Two more patients (3.1%) presented with isolated extracorporeal membrane oxygenation circuit dysfunction requiring circuit change, and one developed bilateral pneumothoraces (1.5%) requiring intercostal drain insertion. Patients who developed complications had significantly lower extracorporeal membrane oxygenation postoxygenator PO2 prior to percutaneous dilatational tracheostomy (45.8 kPa [interquartile range, 36.9-56.5 kPa] vs 57.9 kPa [interquartile range, 45.1-64.2 kPa]; p = 0.019]. On multivariate analysis, including demographic, clinical, biochemical, hematologic variables, and extracorporeal membrane oxygenation circuit functional variables, extracorporeal membrane oxygenation postoxygenator PO2 was the only independent variable associated with major complications following percutaneous dilatational tracheostomy (beta = -0.09; odds ratio, 0.9; 95% CI, 0.84-0.99; p = 0.03).
Percutaneous dilatational tracheostomy is associated with a considerable complication rate in veno-venous extracorporeal membrane oxygenation patients. Preprocedure circuit performance as indicated by extracorporeal membrane oxygenation postoxygenator PO2 is an independent predictor of major complications following percutaneous dilatational tracheostomy.
研究在静脉-静脉体外膜肺氧合支持下,严重呼吸衰竭患者行经皮扩张气管切开术的安全性。
单中心、回顾性、观察性队列研究。
三级转诊严重呼吸衰竭中心,大学教学医院。
2010 年 1 月至 2015 年 12 月期间连续收治并接受静脉-静脉体外膜肺氧合支持的严重呼吸衰竭患者。
所有患者均行支气管镜引导下经皮扩张气管切开术。
共 65 例接受静脉-静脉体外膜肺氧合患者(中位[四分位间距]年龄,47 岁[四分位间距,35-59 岁];39 例男性;急性生理学和慢性健康评估Ⅱ评分,18[四分位间距,17-22]序贯器官衰竭评估评分,10[四分位间距,7-16])接受经皮扩张气管切开术。10 例(15%)患者发生 1 种或多种严重并发症。其中,7 例(11%)发生大出血,其中 3 例还因体外膜肺氧合回路功能障碍而需要更换回路。另外 2 例(3.1%)患者仅出现体外膜肺氧合回路功能障碍,需要更换回路,1 例发生双侧气胸(1.5%),需要肋间引流。发生并发症的患者在经皮扩张气管切开术前体外膜肺氧合后氧合器 PO2 明显较低(45.8 kPa[四分位间距,36.9-56.5 kPa] vs 57.9 kPa[四分位间距,45.1-64.2 kPa];p=0.019)。多变量分析包括人口统计学、临床、生化、血液学变量和体外膜肺氧合回路功能变量,体外膜肺氧合后氧合器 PO2 是经皮扩张气管切开术后发生严重并发症的唯一独立相关因素(β=-0.09;比值比,0.9;95%可信区间,0.84-0.99;p=0.03)。
在静脉-静脉体外膜肺氧合患者中,经皮扩张气管切开术与相当高的并发症发生率相关。体外膜肺氧合后氧合器 PO2 提示的术前回路性能是经皮扩张气管切开术后发生严重并发症的独立预测因子。